IVD are the medical diagnostic devices comprised of any reagent, calibrator, control material, kit, specimen receptacle, software, instrument, apparatus, equipment, or system used alone or in combination with other diagnostic devices, specifically designed for in vitro examination of specimens of human body.
Increase in incidences of chronic and infectious diseases such as tuberculosis, cancer, HIV and others drive the market. Furthermore, rapid expansion of government healthcare expenditure is anticipated to increase the demand of diagnosis, thereby fueling the market growth. In addition, rise in awareness of personalized medicine and increase in awareness of preventive healthcare measures boost the market share. However, stringent government regulations associated with the safety and efficacy of IVD products is expected to hinder the growth of the market during the forecast period. The emerging economies of the LAMEA regions offer lucrative growth opportunities to IVD during the forecast period. The LAMEA IVD market accounted for $7,413 million in 2016, and is estimated to reach at $10,316 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023.
The market is segmented on the basis of product type, techniques, application, end user, and country. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is divided into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point of care testing, and others. By geography, it is analyzed across Latin America, Middle East, and Africa.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the LAMEA IVD market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
Reagents
Instruments
Software and Services
By Techniques
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques
By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications
By End Users
Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others
By Country
Latin America
Middle East
Africa
List of players profiled in the report
Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
